

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

09 Jul 2026

### The effects of melatonin on oxidative pathways in patients with acute ischemic stroke: A randomized double-blind clinical trial

#### Protocol summary

##### Study aim

The effects of melatonin on oxidative pathways in patients with acute ischemic stroke

##### Design

Based on the randomization table (permuted block method in blocks of 4), patients are candidates to receive melatonin or placebo for 5 days. All patients included in the study, who are 60 and placed in parallel groups, will receive a standard treatment regimen.

##### Settings and conduct

Patients with MS referred to Bo Ali Sina Educational Center who meet the inclusion criteria and do not have the exclusion criteria are included in the study and are divided into two groups according to the randomization table and are evaluated for 12 weeks. The treating doctor, the patient and the evaluator are unaware of the type of therapeutic intervention.

##### Participants/Inclusion and exclusion criteria

Adults over 18 years of age with diagnosis of acute ischemic stroke according to brain CT scan findings will be included. Pregnant and lactating women, people with severe psychiatric disorders, severe hepatic insufficiency, NIHSS more than 25, and lacunar infarct will be excluded from the study.

##### Intervention groups

Intervention: Melatonin 30 mg daily for 5 days Control: Placebo (same shape and color) daily for 5 days

##### Main outcome variables

The effectiveness of melatonin on inflammatory biomarkers serum levels reduction, Oxidative stress biomarker serum levels reduction, stroke induced disability improvement according to mRS, Melatonin tolerability

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20190804044429N10**

Registration date: **2023-01-22, 1401/11/02**

Registration timing: **registered\_while\_recruiting**

Last update: **2023-01-22, 1401/11/02**

Update count: **0**

##### Registration date

2023-01-22, 1401/11/02

##### Registrant information

###### Name

Monireh Ghazaeian

###### Name of organization / entity

###### Country

Iran (Islamic Republic of)

###### Phone

+98 21 8863 6864

###### Email address

ghazaeianm@gmail.com

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2023-01-21, 1401/11/01

##### Expected recruitment end date

2023-09-22, 1402/06/31

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

The effects of melatonin on oxidative pathways in patients with acute ischemic stroke: A randomized double-blind clinical trial

##### Public title

Melatonin ischemic stroke

### **Purpose**

Treatment

### **Inclusion/Exclusion criteria**

#### **Inclusion criteria:**

Adults over the age of 18 and diagnose with acute ischemic stroke according to brain CT scan findings  
NIHSS more than 4

#### **Exclusion criteria:**

Hemorrhagic stroke Lacunar infarct TIA NIHSS more than 25  
Pregnancy Lactation Severe hepatic insufficiency  
History of apnea

### **Age**

From **18 years** old

### **Gender**

Both

### **Phase**

2-3

### **Groups that have been masked**

- Participant
- Care provider
- Investigator

### **Sample size**

Target sample size: **60**

### **Randomization (investigator's opinion)**

Randomized

### **Randomization description**

Randomization using the block method by a person who is not related to the study. Packages containing the drug and placebo are completely similar in shape and color. Randomization of serial numbers of drug packages and placebo by a person who is not involved in the project according to randomized table. The number of the bottle corresponded with the number of the patient. Random block method will be used to allocate the samples to two groups. Blocks will be considered as 4 blocks and in each block of 4 people, two people in the intervention group and two people in the control group will be selected. The selection of the order type in each group for each person will be done through second version of random allocation software.

### **Blinding (investigator's opinion)**

Double blinded

### **Blinding description**

This study is double\_ blind. Outcome evaluator and participant are blinded (double blind) and aware from grouping (intervention or placebo)

### **Placebo**

Used

### **Assignment**

Parallel

### **Other design features**

## **Secondary Ids**

empty

## **Ethics committees**

### 1

#### **Ethics committee**

##### **Name of ethics committee**

Mazandaran university of medical Sciences

##### **Street address**

Ibn Sina hospital, Pasdaran Blvd

##### **City**

Sari

##### **Province**

Mazandaran

##### **Postal code**

4816864193

#### **Approval date**

2022-08-10, 1401/05/19

#### **Ethics committee reference number**

IR.MAZUMS.REC.1401.258

## **Health conditions studied**

### 1

#### **Description of health condition studied**

Cerebellar stroke syndrome

#### **ICD-10 code**

G46.4

#### **ICD-10 code description**

Cerebellar stroke syndrome

## **Primary outcomes**

### 1

#### **Description**

Glutathione serum level

#### **Timepoint**

days 0 and 5th of the study

#### **Method of measurement**

Spectroscopy

### 2

#### **Description**

Antioxidant serum levels

#### **Timepoint**

at days 0 and 5th of the study

#### **Method of measurement**

Spectroscopy

## **Secondary outcomes**

### 1

#### **Description**

Disability following stroke

#### **Timepoint**

At days 0, discharge and month three of the study

#### **Method of measurement**

According to mRS

## 2

### **Description**

Tolerability of melatonin

### **Timepoint**

During the study period

### **Method of measurement**

History taking

## **Intervention groups**

### 1

#### **Description**

Intervention group: patients in the intervention group will receive 30 mg melatonin following acute ischemic stroke for 5 days

#### **Category**

Treatment - Drugs

### 2

#### **Description**

Control group: patients in the control group will receive a placebo in the form of tablets with the same color, size and packaging as the intervention group and without the active pharmaceutical ingredient for five days

#### **Category**

Placebo

## **Recruitment centers**

### 1

#### **Recruitment center**

##### **Name of recruitment center**

Ibn Sina hospital

##### **Full name of responsible person**

Monireh Ghazaeian

##### **Street address**

Pasdarán Blvd.

##### **City**

Sari

##### **Province**

Mazandaran

##### **Postal code**

4816864193

##### **Phone**

+98 11 3448 4800

##### **Fax**

+98 11 3334 3989

##### **Email**

ghazaeianm@gmail.com

## **Sponsors / Funding sources**

### 1

#### **Sponsor**

##### **Name of organization / entity**

Mazandaran University of Medical Sciences

##### **Full name of responsible person**

Pedram Ebrahimnejad

##### **Street address**

Vice chancellor for Research, Mazandaran University of Medical Sciences, Joybar 3way, Sari, Iran

##### **City**

Sari

##### **Province**

Mazandaran

##### **Postal code**

4815733971

##### **Phone**

+98 11 3448 4800

##### **Email**

pebrahimnejad@mazums.ac.ir

##### **Grant name**

##### **Grant code / Reference number**

##### **Is the source of funding the same sponsor organization/entity?**

Yes

##### **Title of funding source**

Mazandaran University of Medical Sciences

##### **Proportion provided by this source**

100

##### **Public or private sector**

Public

##### **Domestic or foreign origin**

Domestic

##### **Category of foreign source of funding**

*empty*

##### **Country of origin**

##### **Type of organization providing the funding**

Academic

## **Person responsible for general inquiries**

#### **Contact**

##### **Name of organization / entity**

Mazandaran University of Medical Sciences

##### **Full name of responsible person**

Mazandaran University of Medical Sciences

##### **Position**

Assistant professor

##### **Latest degree**

Specialist

##### **Other areas of specialty/work**

Clinical pharmacy

##### **Street address**

Ibn Sina hospital, Pasdarán Blvd, Sari, Mazandaran province, Iran

##### **City**

Sari

##### **Province**

Mazandaran

##### **Postal code**

4815733971

##### **Phone**

+98 33343011

##### **Email**

Ghazaeianm@gmail.com

## Person responsible for scientific inquiries

### Contact

**Name of organization / entity**

Mazandaran University of Medical Sciences

**Full name of responsible person**

Monireh Ghazaeian

**Position**

Assistant Professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Clinical pharmacy

**Street address**

Ibn Sina hospital, Pasdaran Blvd, Sari, Mazandaran province, Iran

**City**

Sari

**Province**

Mazandaran

**Postal code**

4815733971

**Phone**

+98 11 3334 3011

**Email**

Ghazaeianm@gmail.com

## Person responsible for updating data

### Contact

**Name of organization / entity**

Mazandaran University of Medical Sciences

**Full name of responsible person**

Monireh Ghazaeian

**Position**

Assistant Professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Medical Pharmacy

**Street address**

Ibn Sina hospital, Pasdaran Blvd, Sari, Mazandaran province, Iran

**City**

Sari

**Province**

Mazandaran

**Postal code**

4815733971

**Phone**

+98 11 3334 3011

**Email**

Ghazaeianm@gmail.com

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

**Study Protocol**

Undecided - It is not yet known if there will be a plan to make this available

**Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to make this available

**Informed Consent Form**

Yes - There is a plan to make this available

**Clinical Study Report**

Yes - There is a plan to make this available

**Analytic Code**

Not applicable

**Data Dictionary**

Not applicable

**Title and more details about the data/document**

Data related to the initial outcomes of the study will be shared

**When the data will become available and for how long**

The data will be available one year after publication

**To whom data/document is available**

Academic researchers, medical team and scientific institutes

**Under which criteria data/document could be used**

Requests for sharing data should be sent to the person responsible for general inquiries

**From where data/document is obtainable**

Requests for sharing data should be sent to the person responsible for general inquiries.

Ghazaeianm@gmail.com

**What processes are involved for a request to access data/document**

Person in charge of scientific study will reply to the request within 10 days

**Comments**